HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hnatowich, D.J. Search for Related Content PubMed PubMed Citation Articles by Hnatowich, D.J.

Antisense and Nuclear Medicine

Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

Correspondence: For correspondence or reprints contact: D.J. Hnatowich, PhD, Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester, MA 01655.

ABSTRACT

Despite many uncertainties concerning mechanism, synthetic single-strand antisense deoxyribonucleic acids (DNAs) are now in clinical trials for the chemotherapy of viral infections such as human immunodeficiency virus (HIV) and human papilloma virus; several cancers, including follicular lymphoma and acute myelogenous leukemia; inflammatory processes such as Crohn's disease and rheumatoid arthritis and in allergic disorders. There are approximately 10 trials, and early results are generally encouraging. Therefore, the expectation is that antisense DNAs will be important to future chemotherapy. The question considered here is whether antisense DNAs will also be important to future nuclear medicine imaging. While efforts toward developing antisense imaging are comparatively nonexistent thus far, investigations into the mechanisms of cellular transport and localization and the development of a second generation of antisense DNAs have occurred largely within the antisense chemotherapy industry. Fortunately, many of the properties of DNA for antisense imaging, such as high in vivo stability and adequate cell membrane transport, are the same as those for antisense chemotherapy. Unfortunately, interests diverge in the case of several other key properties. For example, rapid localization and clearance kinetics of the radiolabel and prolonged retention in the target are requirements unique to nuclear medicine. No doubt the development of antisense imaging will continue to benefit from improvements in the antisense chemotherapy industry. However, a considerable effort will be required to optimize this approach for imaging (and radiotherapy). The potential of specifically targeting virtually any disease or normal tissue should make this effort worthwhile.

Key Words: antisense • radiolabeling • deoxyribonucleic acid • imaging

This article has been cited by other articles:

				A. Roivainen, T. Tolvanen, S. Salomaki, G. Lendvai, I. Velikyan, P. Numminen, M. Valila, H. Sipila, M. Bergstrom, P. Harkonen, et al. 68Ga-Labeled Oligonucleotides for In Vivo Imaging with PET J. Nucl. Med., February 1, 2004; 45(2): 347 - 355. [Abstract] [Full Text] [PDF]

				S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]

				H. J. Lee, R. J. Boado, D. A. Braasch, D. R. Corey, and W. M. Pardridge Imaging Gene Expression in the Brain In Vivo in a Transgenic Mouse Model of Huntington's Disease with an Antisense Radiopharmaceutical and Drug-Targeting Technology J. Nucl. Med., July 1, 2002; 43(7): 948 - 956. [Abstract] [Full Text] [PDF]

				Y.-M. Zhang, Y. Wang, N. Liu, Z.-H. Zhu, M. Rusckowski, and D. J. Hnatowich In Vitro Investigations of Tumor Targeting with 99mTc-Labeled Antisense DNA J. Nucl. Med., November 1, 2001; 42(11): 1660 - 1669. [Abstract] [Full Text] [PDF]

				J.-L. C. Urbain Sense, Antisense, and Common Sense J. Nucl. Med., November 1, 2001; 42(11): 1670 - 1672. [Full Text] [PDF]

				N. Shi, R. J. Boado, and W. M. Pardridge Antisense imaging of gene expression in the brain in vivo PNAS, December 19, 2000; 97(26): 14709 - 14714. [Abstract] [Full Text] [PDF]